These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38369241)

  • 1. A narrative review about cognitive impairment in metabolic Dysfunction-Associated liver disease (MASLD): Another matter to face through a holistic approach.
    Meroni M; Longo M; Paolini E; Dongiovanni P
    J Adv Res; 2024 Feb; ():. PubMed ID: 38369241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
    Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
    JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD).
    Benedé-Ubieto R; Cubero FJ; Nevzorova YA
    Gut Microbes; 2024; 16(1):2331460. PubMed ID: 38512763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function.
    Medina-Julio D; Ramírez-Mejía MM; Cordova-Gallardo J; Peniche-Luna E; Cantú-Brito C; Mendez-Sanchez N
    Med Sci Monit; 2024 Jan; 30():e943417. PubMed ID: 38282346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status and future trends of the global burden of MASLD.
    Miao L; Targher G; Byrne CD; Cao YY; Zheng MH
    Trends Endocrinol Metab; 2024 Feb; ():. PubMed ID: 38429161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pathophysiology of MASLD: an immunometabolic perspective.
    Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H
    Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAD metabolic therapy in metabolic dysfunction-associated steatotic liver disease: Possible roles of gut microbiota.
    Lu X; Yang R; Chen Y; Chen D
    iScience; 2024 Mar; 27(3):109174. PubMed ID: 38405608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression.
    Jaeger JW; Brandt A; Gui W; Yergaliyev T; Hernández-Arriaga A; Muthu MM; Edlund K; Elashy A; Molinaro A; Möckel D; Sarges J; Halibasic E; Trauner M; Kahles F; Rolle-Kampczyk U; Hengstler J; Schneider CV; Lammers T; Marschall HU; von Bergen M; Camarinha-Silva A; Bergheim I; Trautwein C; Schneider KM
    JHEP Rep; 2024 Mar; 6(3):100987. PubMed ID: 38328439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes.
    Godoy-Matos AF; Valério CM; Silva Júnior WS; de Araujo-Neto JM; Bertoluci MC
    Diabetol Metab Syndr; 2024 Jan; 16(1):23. PubMed ID: 38238868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal IL-33 promotes microbiota-derived trimethylamine N -oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1α.
    Hai S; Li X; Xie E; Wu W; Gao Q; Yu B; Hu J; Xu F; Zheng X; Zhang BH; Wu D; Yan W; Ning Q; Wang X
    Hepatology; 2024 Jul; ():. PubMed ID: 38985971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Adipose Tissue-Liver-Gut Microbiota Crosstalk to Cure MASLD.
    Gabbia D; De Martin S
    Biology (Basel); 2023 Nov; 12(12):. PubMed ID: 38132297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Shin S; Kim J; Lee JY; Kim J; Oh CM
    J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.
    Chan WK; Chuah KH; Rajaram RB; Lim LL; Ratnasingam J; Vethakkan SR
    J Obes Metab Syndr; 2023 Sep; 32(3):197-213. PubMed ID: 37700494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease.
    Mak AL; Wassenaar N; van Dijk AM; Troelstra M; Houttu V; van Son K; Driessen S; Zwirs D; van den Berg-Faay S; Shumbayawonda E; Runge J; Doukas M; Verheij J; Beuers U; Nieuwdorp M; Cahen DL; Nederveen A; Gurney-Champion O; Holleboom A
    JHEP Rep; 2024 Mar; 6(3):100998. PubMed ID: 38379586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus.
    Forlano R; Martinez-Gili L; Takis P; Miguens-Blanco J; Liu T; Triantafyllou E; Skinner C; Loomba R; Thursz M; Marchesi JR; Mullish BH; Manousou P
    Gut Microbes; 2024; 16(1):2304157. PubMed ID: 38235661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diet, exercise, and supplements: what is their role in the management of the metabolic dysfunction-associated steatotic liver disease in children?
    Serbis A; Polyzos SA; Paschou SA; Siomou E; Kiortsis DN
    Endocrine; 2024 Mar; ():. PubMed ID: 38519764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut Microbiota and Sinusoidal Vasoregulation in MASLD: A Portal Perspective.
    Baffy G; Portincasa P
    Metabolites; 2024 Jun; 14(6):. PubMed ID: 38921459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic dysfunction-associated steatotic liver disease and atherosclerosis.
    Castillo-Núñez Y; Almeda-Valdes P; González-Gálvez G; Arechavaleta-Granell MDR
    Curr Diab Rep; 2024 Jul; 24(7):158-166. PubMed ID: 38700793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.